Evidence map›Paper›PMID 37961176›Full record

ArticlebioRxiv : the preprint server for biology2023

MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer.

Shrey Ramesh, Ahmet Cifci, Saahil Javeri, Rachel Minne, Colin A Longhurst, Kwangok P Nickel, Randall J Kimple, Andrew M Baschnagel

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Shrey RameshDepartment of Human Oncology, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.
Ahmet CifciDepartment of Human Oncology, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.
Saahil JaveriDepartment of Human Oncology, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.
Rachel MinneDepartment of Human Oncology, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.
Colin A LonghurstDepartment of Biostatistics and Medical Informatics, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.
Kwangok P NickelDepartment of Human Oncology, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.
Randall J KimpleDepartment of Human Oncology, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.
Andrew M BaschnagelDepartment of Human Oncology, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.
University of Wisconsin–Madison · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6M
Improving the translational value of head and neck cancer patient-in-mouse modelsR37CA255330 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Randall J. Kimple · 2021 to 2026
$3.5M
NCI NIH HHS P30 CA014520NCI NIH HHS R37 CA255330
6 · The paper itself

Abstract

Purpose: The objective of this study was to investigate the effects of inhibiting the MET receptor with capmatinib, a potent and clinically relevant ATP-competitive tyrosine kinase inhibitor, in combination with radiation in MET exon 14-mutated and MET-amplified non-small cell lung (NSCLC) cancer models. Methods and Materials: Results: Conclusions: Inhibition of MET with capmatinib enhanced the effect of radiation in both MET exon 14-mutated and MET-amplified NSCLC models.

Indexed as

capmatinibMETMET exon 14non-small cell lung cancerradiation

Identifiers

PMID37961176
PMCPMC10634863
OpenAlexW4387969923

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.